Literature DB >> 24415967

AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013.

Nadia Harbeck1, Anton Scharl2, Christoph Thomssen3, Volkmar Müller4.   

Abstract

Entities:  

Keywords:  Guidelines; Locoregional relapse; Metastatic breast cancer; Targeted therapy

Year:  2013        PMID： 24415967      PMCID： PMC3728631          DOI： 10.1159/000353590

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  39 in total

Review 1.  Resection of liver metastases from breast cancer: towards a management guideline.

Authors:  Mohammad Howlader; Nigel Heaton; Mohamed Rela
Journal:  Int J Surg       Date:  2011-01-31       Impact factor: 6.071

2.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

3.  Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.

Authors:  Hans-Georg Kopp; Katja Krauss; Tanja Fehm; Annette Staebler; Jennifer Zahm; Wichard Vogel; Lothar Kanz; Frank Mayer
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

4.  Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study.

Authors:  Sabine Oldenborg; Rob M Van Os; Caroline M Van rij; Johannes Crezee; Jeroen B Van de Kamer; Emiel J T Rutgers; Elisabeth D Geijsen; Paul J Zum vörde sive vörding; Caro C E Koning; Geertjan Van tienhoven
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

5.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Elizabeth A Mittendorf; Yun Gong; Shana L Palla; Yutaka Tokuda; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

6.  Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Authors:  Rupert Bartsch; Zsuzsanna Bago-Horvath; Anna Berghoff; Catharina DeVries; Ursula Pluschnig; Peter Dubsky; Margaretha Rudas; Robert M Mader; Andrea Rottenfusser; Florian Fitzal; Michael Gnant; Christoph C Zielinski; Guenther G Steger
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

Review 7.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Authors:  May N Tsao; Nancy Lloyd; Rebecca K S Wong; Edward Chow; Eileen Rakovitch; Normand Laperriere; Wei Xu; Arjun Sahgal
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 8.  Thermal ablation therapies in patients with breast cancer liver metastases: a review.

Authors:  Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Stephan Zangos
Journal:  Eur Radiol       Date:  2012-10-13       Impact factor: 5.315

9.  Association of surgery with improved survival in stage IV breast cancer patients.

Authors:  D Kay Blanchard; Priya B Shetty; Susan G Hilsenbeck; Richard M Elledge
Journal:  Ann Surg       Date:  2008-05       Impact factor: 12.969

10.  Combination anastrozole and fulvestrant in metastatic breast cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2012-08-02       Impact factor: 91.245
View more
  2 in total

1.  Guidelines: usefulness and limitations.

Authors:  Michael Gnant
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

Review 2.  Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.

Authors:  Katrin Almstedt; Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2015-05-13       Impact factor: 2.860
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.